P163 Efficacy of deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, in musculoskeletal manifestations of systemic lupus erythematosus: a subanalysis of the phase 2 PAISLEY study

• Richard Furie,
• Peter Nash,
• Amit Saxena,
• Thomas Dörner,
• Subhashis Banerjee,
• Joan Merrill,
• Marilyn Pike,
• Coburn Hobar,
• Samantha Pomponi,
• Ravi Koti,
• Thomas Wegman

Affiliations

Richard Furie

3Division of Rheumatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, USA

Peter Nash

School of Medicine, Griffith University, Brisbane, Queensland, Australia

Amit Saxena

2 Rheumatology, NYU Grossman School of Medicine, New York City, New York, USA

Thomas Dörner

1Rheumatology and Clinical Immunology, Charité- University Medicine Berlin, Germany

Subhashis Banerjee

7 Bristol Myers Squibb, Princeton, New Jersey, USA

Joan Merrill

Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA

Marilyn Pike

6Massachussetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

Coburn Hobar

6Bristol Myers Squibb, Princeton, NJ, USA

Samantha Pomponi

6Bristol Myers Squibb, Princeton, NJ, USA

Ravi Koti

7Syneos Health, Morrisville, NC, USA

Thomas Wegman

6Bristol Myers Squibb, Princeton, NJ, USA